|
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. |
|
|
Consulting or Advisory Role - Astellas Pharma |
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; SERVIER |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Sanofi; SERVIER |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Novartis; Sanofi |
Research Funding - Bayer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck; Merck Serono; Sanofi |
|
|
Consulting or Advisory Role - Astellas Pharma; Five Prime Therapeutics; Merck; Taiho Pharmaceutical |
|
|
Honoraria - Oncolys BioPharma |
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst) |
|
|
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst) |
|
|
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche |
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche |
|
|
Honoraria - Amgen; Bayer; Lilly; Novartis; Sanofi |
Consulting or Advisory Role - Merck Serono; Roche; SERVIER |
Travel, Accommodations, Expenses - Roche; SERVIER |
|
|
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical |
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Research Funding - Boehringer Ingelheim; MSD; Taiho Pharmaceutical; Takeda; Yakult Honsha |
|
|
Consulting or Advisory Role - Enzychem Lifesciences (Inst); Lilly (Inst); Novartis (Inst); Odonate Therapeutics (Inst) |
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis |
|
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical |
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst) |
|
|
Consulting or Advisory Role - Jiangsu Hengrui Medicine |
Research Funding - Jiangsu Hengrui Medicine |
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - MSD; Novartis |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Health; Lilly |
Consulting or Advisory Role - Erytech Pharma; Sanofi |
Research Funding - Bristol-Myers Squibb; Merck |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; MSD; Novartis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst) |